Stock listing
NASDAQ:AVR Anteris Technologies Global Corp. Stock
Home listing (NASDAQ) of Anteris Technologies Global Corp.
Follow Anteris Technologies Global Corp. into a list and get an email when it puts out news.
Share price · NASDAQ:AVR
$4.99 USD -0.22 (-4.2%)
Close on Nov 20, 2026
- Day range
- $4.92 – $5.18 USDNov 20, 2026
- Volume
- 1.54M sharesNov 20, 2026
- Market cap
- $486.5M USDAt the close on Nov 20, 2026 · price × 97.49M shares outstanding
- 52-week range
- $3.30 – $11.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.91M USDMedian day 965,161 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVR · Home | $4.99 USD | -0.22 (-4.2%) | 1,537,886 | $5.05 | $5.18 | $4.92 | $5.21 | Close on Nov 20, 2026 |
| ASX:AVR | $7.55 AUD | -0.33 (-4.2%) | 6,503 | $7.81 | $7.81 | $7.55 | $7.88 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.99 | -0.22 | -4.2% | $5.05 | $5.18 | $4.92 | 1,537,886 | |
| $5.21 | -0.11 | -2.1% | $5.28 | $5.43 | $5.13 | 1,235,045 | |
| $5.32 | -0.38 | -6.7% | $5.63 | $5.66 | $5.28 | 1,179,226 | |
| $5.70 | +0.28 | +5.2% | $5.48 | $5.72 | $5.40 | 1,341,441 | |
| $5.42 | -0.44 | -7.5% | $5.81 | $5.81 | $5.35 | 1,471,123 | |
| $5.86 | -0.34 | -5.5% | $6.15 | $6.255 | $5.82 | 965,161 | |
| $6.20 | +0.31 | +5.3% | $6.07 | $6.23 | $6.005 | 751,543 | |
| $5.89 | -0.05 | -0.8% | $5.85 | $6.02 | $5.77 | 778,730 | |
| $5.94 | +0.25 | +4.4% | $5.76 | $6.03 | $5.69 | 669,389 | |
| $5.69 | +0.11 | +2.0% | $5.55 | $5.79 | $5.47 | 1,213,514 | |
| $5.58 | -0.54 | -8.8% | $6.13 | $6.20 | $5.45 | 1,851,297 | |
| $6.12 | +0.52 | +9.3% | $5.66 | $6.13 | $5.66 | 1,156,591 | |
| $5.60 | -0.18 | -3.1% | $5.77 | $5.875 | $5.58 | 1,170,914 | |
| $5.78 | -0.53 | -8.4% | $6.55 | $6.562 | $5.255 | 4,017,767 | |
| $6.31 | -0.11 | -1.7% | $6.33 | $6.37 | $6.11 | 1,395,367 | |
| $6.42 | +0.32 | +5.2% | $6.05 | $6.42 | $6.05 | 2,818,538 | |
| $6.10 | +0.10 | +1.7% | $5.96 | $6.17 | $5.91 | 1,542,723 | |
| $6.00 | +0.22 | +3.8% | $5.78 | $6.075 | $5.77 | 1,480,448 | |
| $5.78 | -0.09 | -1.5% | $5.85 | $5.92 | $5.74 | 739,306 | |
| $5.87 | -0.13 | -2.2% | $6.00 | $6.08 | $5.85 | 901,787 | |
| $6.00 | -0.01 | -0.2% | $5.92 | $6.17 | $5.825 | 2,096,160 | |
| $6.01 | -0.28 | -4.5% | $6.29 | $6.47 | $5.99 | 1,392,713 | |
| $6.29 | +0.11 | +1.8% | $6.20 | $6.525 | $6.175 | 2,830,358 | |
| $6.18 | +0.13 | +2.1% | $6.09 | $6.25 | $6.06 | 1,358,818 | |
| $6.05 | -0.31 | -4.9% | $6.34 | $6.34 | $6.04 | 1,032,900 | |
| $6.36 | +0.10 | +1.6% | $6.23 | $6.38 | $6.115 | 825,700 | |
| $6.26 | -0.19 | -2.9% | $6.33 | $6.468 | $6.095 | 1,740,000 | |
| $6.45 | -0.20 | -3.0% | $6.61 | $6.635 | $6.41 | 764,200 | |
| $6.65 | -0.12 | -1.8% | $6.72 | $6.763 | $6.525 | 972,500 | |
| $6.77 | +0.14 | +2.1% | $6.73 | $6.90 | $6.64 | 1,342,000 | |
| $6.63 | -0.19 | -2.8% | $6.75 | $6.78 | $6.565 | 2,470,200 | |
| $6.82 | -0.23 | -3.3% | $6.83 | $7.08 | $6.76 | 2,454,100 | |
| $7.05 | -0.50 | -6.6% | $7.57 | $7.655 | $7.02 | 2,641,700 | |
| $7.55 | -0.16 | -2.1% | $7.66 | $7.745 | $7.365 | 1,892,800 | |
| $7.71 | +0.10 | +1.3% | $7.97 | $8.00 | $7.655 | 1,495,600 | |
| $7.61 | -0.16 | -2.1% | $7.74 | $7.86 | $7.52 | 1,170,700 | |
| $7.77 | +0.18 | +2.4% | $7.66 | $7.955 | $7.54 | 976,400 | |
| $7.59 | -0.15 | -1.9% | $7.80 | $7.84 | $7.525 | 782,400 | |
| $7.74 | +0.05 | +0.7% | $7.63 | $7.755 | $7.555 | 707,200 | |
| $7.69 | +0.04 | +0.5% | $7.65 | $7.84 | $7.49 | 762,700 | |
| $7.65 | +0.03 | +0.4% | $7.60 | $7.695 | $7.47 | 779,000 | |
| $7.62 | -0.51 | -6.3% | $8.03 | $8.035 | $7.57 | 867,200 | |
| $8.13 | -0.02 | -0.2% | $8.27 | $8.32 | $8.055 | 842,900 | |
| $8.15 | -0.01 | -0.1% | $8.20 | $8.24 | $7.99 | 741,800 | |
| $8.16 | -0.26 | -3.1% | $8.40 | $8.57 | $8.12 | 1,809,000 | |
| $8.42 | +0.05 | +0.6% | $8.50 | $8.60 | $8.35 | 445,000 | |
| $8.37 | +0.03 | +0.4% | $8.36 | $8.47 | $8.26 | 968,200 | |
| $8.34 | -0.38 | -4.4% | $8.68 | $8.71 | $8.30 | 583,600 | |
| $8.72 | +0.37 | +4.4% | $8.32 | $8.73 | $8.255 | 551,800 | |
| $8.35 | +0.05 | +0.6% | $8.41 | $8.565 | $8.10 | 640,300 | |
| $8.30 | -0.23 | -2.7% | $8.35 | $8.45 | $8.23 | 842,300 | |
| $8.53 | -0.09 | -1.0% | $8.58 | $8.74 | $8.50 | 681,900 | |
| $8.62 | -0.42 | -4.6% | $9.04 | $9.04 | $8.61 | 490,500 | |
| $9.04 | +0.32 | +3.7% | $8.665 | $9.101 | $8.66 | 362,900 | |
| $8.72 | +0.13 | +1.5% | $8.72 | $8.755 | $8.46 | 533,400 | |
| $8.59 | +0.14 | +1.7% | $8.50 | $8.86 | $8.493 | 470,400 | |
| $8.45 | -0.16 | -1.9% | $8.48 | $8.63 | $8.41 | 568,600 | |
| $8.61 | -0.13 | -1.5% | $8.66 | $8.745 | $8.43 | 755,100 | |
| $8.74 | -0.23 | -2.6% | $9.045 | $9.065 | $8.69 | 533,500 | |
| $8.97 | +0.02 | +0.2% | $8.95 | $9.372 | $8.91 | 469,500 | |
| $8.95 | +0.06 | +0.7% | $8.86 | $9.045 | $8.75 | 558,800 | |
| $8.89 | +0.09 | +1.0% | $8.86 | $8.959 | $8.718 | 515,200 | |
| $8.80 | -0.18 | -2.0% | $8.89 | $8.96 | $8.61 | 802,500 | |
| $8.98 | -0.27 | -2.9% | $9.41 | $9.41 | $8.95 | 566,600 | |
| $9.25 | -0.58 | -5.9% | $9.68 | $9.89 | $9.085 | 1,171,500 |
- Ticker
- NASDAQ:AVR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 22, 2026
Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
Latest deck · Jan 12, 2026
JP Morgan 44th Annual Healthcare Conference (January 2026)
Conference · 31 slides
Latest news
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Nov 16, 2026
Closed $5.70 (+5.2%) on Nov 16, 2026
Anteris Technologies Announces Results for the Third Quarter of 2026
Nov 10, 2026
Closed $6.20 (+5.3%) on Nov 11, 2026
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Nov 1, 2026
Closed $5.78 (-8.4%) on Nov 2, 2026
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Oct 27, 2026
Closed $6.00 (+3.8%) on Oct 27, 2026
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Oct 19, 2026
Closed $6.29 (+1.8%) on Oct 20, 2026
Anteris to Present at September Healthcare Investor Conferences
Aug 31, 2026
Closed $8.61 (-1.5%) on Aug 31, 2026
Anteris Technologies Announces Results for the Second Quarter of 2026
Aug 11, 2026
Closed $8.87 (-3.3%) on Aug 12, 2026
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Jun 8, 2026
Closed $9.34 (-3.1%) on Jun 8, 2026
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
May 13, 2026
Closed $6.53 (-2.5%) on May 13, 2026
Anteris Technologies Global Corp. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 19 in the last 12 months · 36 in all · newest Nov 22, 2026 · oldest 2024
- Decks
- 28 decks · latest Jan 12, 2026
Where Anteris Technologies Global Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVR · Home listing · This page | NASDAQ | United States | USD |
| ASX:AVR | ASX | Australia | AUD |
| BOATS:AVR | BOATS | United States | USD |
Valuation
EV/sales 116× against a median of 4.8×: the highest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $269.6M USD
- P/E
- Loss
- EV/sales
- 116×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- 39.3%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.43
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Anteris Technologies Global Corp. · NASDAQ:AVR | US$486.5M | US$269.6M | n/a | 116× | n/a | 2.1× | n/a | 0.0× | 1.43 |
| Jin Medical International Ltd. · NASDAQ:ZJYL | US$518.6M | US$509.1M | 435× | 24.6× | 598× | 17.1× | 5.8% | 0.7× | 0.92 |
| Ion Beam Applications SA · EURONEXT:IBAB | US$511.8M | US$593.9M | 36.6× | 0.9× | 12.9× | 3.9× | 2.1% | 1.0× | n/a |
| Zhejiang Gongdong Medical Technology Co. Ltd. Class A · SSE:605369 | US$510.9M | US$406.8M | 47.7× | 2.3× | n/a | 2.0× | 6.0% | 0.0× | n/a |
| Contec Medical Systems Co. Ltd. Class A · SZSE:300869 | US$505.5M | US$347.9M | n/a | 4.9× | n/a | 2.0× | −19.1% | 0.5× | n/a |
| Beijing Chunlizhengda Medical Instruments Co., Ltd. Class A · SSE:688236 | US$493.5M | US$175.1M | 12.1× | 1.1× | 3.5× | 1.1× | 26.1% | 0.0× | n/a |
| Avita Medical, Inc. · NASDAQ:RCEL | US$490.8M | US$525.8M | n/a | 6.2× | n/a | n/a | −42.6% | n/a | 1.37 |
| Chimin Health Management Co., Ltd. Class A · SSE:603222 | US$486.8M | US$483.5M | n/a | 5.0× | n/a | 3.1× | −39.2% | 0.2× | n/a |
| Carlsmed, Inc. · NASDAQ:CARL | US$477.4M | US$432.8M | n/a | 6.0× | n/a | 6.3× | −55.8% | 0.2× | 1.34 |
| Nanjing Vishee Medical Technology Co., Ltd. Class A · SSE:688580 | US$463.0M | US$332.3M | 19.5× | 4.8× | n/a | 1.8× | 34.3% | 0.0× | n/a |
| Shanghai Aohua Photoelectricity Endoscope Co. Ltd. Class A · SSE:688212 | US$458.2M | US$416.9M | n/a | 3.5× | n/a | 2.5× | −3.8% | 0.0× | n/a |
| Median of the others | US$492.2M | US$424.8M | 36.6× | 4.8× | 12.9× | 2.5× | −0.9% | 0.2× | 1.34 |
Forecasts
4 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.18 · 5 analysts
- Revenue, year to Dec 2026
- 10.2M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Wayne Paterson | Vice Chairman & CEO |
| Brent Moen | Chief Financial Officer |
| David St Denis | President & Director |
| Eric Schwartz | Chief Legal Officer |
| Debbie Ormsby | Global Investor Relations |
| Malini Chatterjee | Investor Relations US |
| Chris Meduri | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| David St Denis | President & Director |
| Wayne Paterson | Vice Chairman & CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +5.3% |
| Q2 2026 | Aug 11, 2026 · After close | −3.3% |
| Q1 2026 | May 13, 2026 | +8.2% |
| Q4 2025 | Feb 26, 2026 · After close | +2.7% |
| Q3 2025 | Nov 12, 2025 · After close | −2.6% |
| Q2 2025 | Aug 11, 2025 · After close | +6.0% |
| Q1 2025 | May 13, 2025 · After close | −9.9% |
| Q4 2024 | Feb 26, 2025 | −1.7% |
| Q3 2024 | Nov 27, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| JP Morgan 44th Annual Healthcare Conference (January 2026) | Conference | 31 slides | Jan 12, 2026 |
| Shareholder Meeting (December 2025) | Shareholder meeting | 59 slides | Dec 4, 2025 |
| Shareholder Meeting (December 2025) | Shareholder meeting | 57 slides | December 2025 |
| PCR London Valves 2025 | Conference | 16 slides | Nov 18, 2025 |
| Investor Presentation (October 2025) | Investor deck | 31 slides | October 2025 |
| PCR London Valves 2025 | Conference | 19 slides | 2025 |
| IPO Roadshow (December 2024) | IPO roadshow | 34 slides | Dec 16, 2024 |
| EuroPCR 2024 | Conference | 13 slides | Aug 19, 2024 |
| Shareholder Meeting (May 2024) | Shareholder meeting | 80 slides | May 29, 2024 |
| Shareholder Meeting (May 2024) | Shareholder meeting | 77 slides | May 29, 2024 |
All 28 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Annual J.P. Morgan Healthcare Conference 2024 | Conference | 25 slides | Jan 9, 2024 |
| London Valves 2024 | Conference | 13 slides | 2024 |
| TCT 2024 | Conference | 13 slides | 2024 |
| Technical Presentation (November 2023) | Technical | 9 slides | Nov 19, 2023 |
| TVT 2023 | Conference | 13 slides | Oct 13, 2023 |
| Shareholder Meeting (May 2023) | Shareholder meeting | 88 slides | May 29, 2023 |
| Shareholder Meeting (May 2023) | Shareholder meeting | 86 slides | May 29, 2023 |
| NWR Virtual Healthcare Conference 2023 | Conference | 33 slides | Mar 21, 2023 |
| TVT 2023 | Conference | 13 slides | 2023 |
| PCR London Valves 2022 | Conference | 13 slides | Dec 8, 2022 |
| PCR London Valves 2022 | Conference | 10 slides | Nov 18, 2022 |
| Shareholder Meeting (May 2022) | Shareholder meeting | 81 slides | May 25, 2022 |
| Shareholder Meeting (May 2022) | Shareholder meeting | 83 slides | May 25, 2022 |
| Shareholder Meeting (July 2021) | Shareholder meeting | 38 slides | Jul 15, 2021 |
| Shareholder Meeting (July 2021) | Shareholder meeting | 41 slides | Jul 15, 2021 |
| Symposium on Next Generation Technologies (July 2020) | Conference | 11 slides | Jul 21, 2020 |
| Shareholder Meeting (May 2020) | Shareholder meeting | 34 slides | May 2020 |
| Admedus — Shareholder Meeting (2019) | Shareholder meeting | 40 slides | 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$200M raised · US$5.75 a share · Barclays +3 Dealers: Barclays (co-lead), Wells Fargo Securities (co-lead), Cantor (co-lead), Barrenjoey Markets Pty Limited Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve | Jan 22, 2026 |
| Strategic investment of common stock Closed: US$90M raised · Wells Fargo Securities Dealers: Wells Fargo Securities (lead) Buyers: Medtronic plc (up to $90.0 million of shares, 16.0% to 19.99% of shares outstanding after the Offering); Medtronic, plc ($90 million strategic investment) Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve | Jan 22, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.00 a share on Dec 12, 2024.
- Price
- US$6.00 a share
- Shares offered
- 14,800,000 shares of common stock
- Offering size
- US$88.8 million
- Underwriters' option
- Up to 2,220,000 more shares
- Listing
- AVR on the Nasdaq Global Market
- Underwriters
- TD Cowen, Barclays, Cantor, Lake Street · In the order on the cover
- Shares delivered
- On or about Dec 16, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2024 |
| Filed publicly | Nov 22, 2024 |
| Amended once | Dec 9, 2024 |
| Shares registered with an exchange | Dec 10, 2024 |
| Declared effective by the SEC | Dec 12, 2024 |
| Final prospectus, with the price | Dec 13, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 13, 2024 |
| EFFECT · Notice that a registration is effective | Dec 12, 2024 |
| CERT · Exchange's certificate of listing | Dec 12, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 10, 2024 |
| CORRESP · Letter to the SEC | Dec 10, 2024 |
| CORRESP · Letter to the SEC | Dec 10, 2024 |
| S-1/A · Registration statement, amended | Dec 9, 2024 |
| S-1 · Registration statement | Nov 22, 2024 |
| CORRESP · Letter to the SEC | Nov 22, 2024 |
| UPLOAD · Letter from the SEC | Nov 19, 2024 |
All 21 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Nov 4, 2024 |
| DRSLTR · Letter to the SEC with a draft | Nov 1, 2024 |
| UPLOAD · Letter from the SEC | Oct 28, 2024 |
| DRSLTR · Letter to the SEC with a draft | Oct 11, 2024 |
| DRS/A · Draft registration statement, amended | Oct 11, 2024 |
| UPLOAD · Letter from the SEC | Aug 26, 2024 |
| DRSLTR · Letter to the SEC with a draft | Aug 9, 2024 |
| DRS/A · Draft registration statement, amended | Aug 9, 2024 |
| UPLOAD · Letter from the SEC | Jun 10, 2024 |
| DRS/A · Draft registration statement, amended | May 13, 2024 |
| DRS · Draft registration statement | Feb 14, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 13, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.91M | 2.70M | 2.73M | 3.20M | 5.83M | 5.46M |
| Cost of revenue | 569.0K | 1.44M | 1.86M | 2.90M | 3.93M | 2.10M |
| Gross profit | -317.0K | 1.27M | 876.8K | 298.4K | 1.91M | 3.36M |
| Research and development | 69.1M | 51.5M | 31.0M | 17.6M | 9.99M | 3.57M |
| Selling, general and administrative | 26.1M | 28.2M | 16.0M | 14.4M | 8.72M | 2.18M |
| Operating income | -93.9M | -78.4M | -48.1M | -31.1M | -16.9M | -13.3M |
| Depreciation and amortization | 1.66M | 1.51M | 1.16M | 774.1K | 640.1K | 1.01M |
| EBITDA | -92.2M | -76.9M | -47.0M | -30.3M | -16.2M | -12.3M |
| Interest expense | 73.0K | 47.0K | 67.1K | 648.7K | 1.03M | 300.6K |
| Income before tax | -94.2M | -76.0M | -46.8M | -30.6M | -17.2M | -11.8M |
| Income tax | 0 | 0 | ||||
| Net income | -94.1M | -76.3M | -46.0M | -30.6M | -17.2M | -11.8M |
| Earnings per share, basic | -2.55 | -3.68 | -1.28 | -0.85 | -0.48 | -0.33 |
| Earnings per share, diluted | -2.55 | -3.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 6.70M | 70.5M | 21.1M | 9.35M | 15.5M | 3.36M |
| Receivables | 32.0K | 208.0K | 1.13M | 563.7K | 1.85M | 652.4K |
| Inventory | 152.0K | 513.0K | 442.3K | 355.6K | 549.8K | 534.7K |
| Current assets | 15.7M | 74.7M | 24.2M | 12.2M | 18.7M | 6.24M |
| Property, plant and equipment | 5.26M | 4.77M | ||||
| Total assets | 23.0M | 80.7M | 30.5M | 16.0M | 21.4M | 9.75M |
| Accounts payable | 11.1M | 5.89M | 3.14M | 1.73M | 2.23M | 581.9K |
| Current liabilities | 21.4M | 16.6M | 9.46M | 6.05M | 10.2M | 6.04M |
| Long-term debt | 22.0K | 0 | 93.8K | |||
| Total debt | 16.0K | 3.00K | 1.69M | 952.8K | 4.14M | 2.92M |
| Total liabilities | 23.3M | 18.0M | 11.6M | 6.95M | 10.9M | 7.90M |
| Shareholders' equity | -93.0K | 62.8M | 19.3M | 9.03M | 10.5M | 1.86M |
| Shares outstanding | 41.6M | 35.9M | 35.9M | 35.9M | 35.9M | 35.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2015 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -77.8M | -61.2M | -34.6M | -29.4M | -14.4M | -11.1M | |
| Capital spending | -1.95M | -2.27M | -2.39M | -1.67M | -582.2K | -222.5K | 0 |
| Free cash flow | -79.8M | -63.5M | -37.0M | -31.1M | -15.0M | -11.3M | |
| Cash from investing | -596.0K | -2.28M | -2.58M | -992.6K | -886.1K | 5.99M | |
| Cash from financing | 20.6M | 112.8M | 49.3M | 23.3M | 27.4M | 1.46M | |
| Share buybacks | -2.74M | -998.5K | |||||
| Change in cash | -57.9M | 49.4M | 11.7M | -6.10M | 12.1M | -2.94M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Nov 17, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 17, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Nov 9, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 9, 2026 | Meeting notice | SEC |
| 10-Q/A · Quarterly report, amended | Nov 9, 2026 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 9, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Nov 9, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
All 198 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Oct 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 24, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 23, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Sep 21, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 9, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 12, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Jul 1, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| 8-K · Current report | May 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 22, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | May 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 19, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Management or board change | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Apr 30, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Apr 27, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Mar 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 16, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 10, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 29, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jan 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 21, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| FWP · Free writing prospectus | Jan 21, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Jan 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 9, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 2, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 4, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| S-1 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Nov 10, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 10, 2025 | Annual report | SEC |
| D | Nov 7, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| 8-K · Current report | Oct 27, 2025 | Financing | SEC |
| 8-K · Current report | Oct 24, 2025 | Financing | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 29, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 19, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 4, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Aug 18, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| 8-K · Current report | Jul 29, 2025 | Material contract | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Mar 21, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 21, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 8-K · Current report | Mar 12, 2025 | Results | SEC |
| 10-K · Annual report | Mar 12, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Dec 17, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Dec 16, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 16, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Management or board change | SEC |
| 424B4 · Prospectus | Dec 13, 2024 | Offer document | SEC |
| POS EX | Dec 13, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 13, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Dec 12, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Dec 12, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Dec 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 9, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Dec 5, 2024 | Other filings | SEC |
| S-1 · Registration statement | Nov 22, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 19, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Nov 1, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Nov 1, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 28, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 11, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Oct 11, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 9, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 9, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | May 13, 2024 | Offer document | SEC |
| DRS · Draft registration statement | Feb 14, 2024 | Offer document | SEC |
Cap table
Built by 6ix from Anteris Technologies Global Corp.’s releases · as of Nov 9, 2026
- Common shares
- 97,493,429
- Fully diluted
- 97,493,429
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 97,493,429 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 97,493,429 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gregory S. Moss Other companies: Evommune, Inc. (Chief Business and Legal Officer · Since at least Nov 5, 2025); Kadmon Holdings Inc (EVP, Gen. Coun. / CCO. · Aug 30, 2019 – Nov 9, 2021 · Past) | Director · Since at least Jun 7, 2025 |
| David B. Roberts Other companies: LeMaitre Vascular, Inc. (President and Director, Director · Since at least Oct 21, 2020) | Director · Since at least Jun 7, 2025 |
| John D Seaberg Other companies: Synovis Life Technologies Inc (Director · Oct 28, 2011 – Oct 28, 2011 · Past) | Director · Since at least Dec 10, 2024 |
| Brent Moen | Chief Financial Officer · Since at least Nov 5, 2026 |
| Christopher Meduri | Chief Medical Officer · Since at least Nov 1, 2026 |
| David St Denis | Chief Operating Officer, Director · Since at least Dec 16, 2025 |
| Debbie Ormsby | Global Investor Relations · Since at least Oct 27, 2026 |
| Eric Schwartz | Chief Legal Officer · Since at least Nov 5, 2026 |
| Malini Chatterjee | Investor Relations US · Since at least Oct 27, 2026 |
| Matthew McDonnell | Chief Financial Officer · Since at least Dec 10, 2024 |
All 14 people
| Person | Seat |
|---|---|
| Stephen Denaro | Director · Since at least Dec 10, 2024 |
| Susan Elizabeth Knight | Director · Since at least Jun 2, 2026 |
| Wayne Paterson | Vice Chairman & CEO · Since at least Oct 20, 2026 |
| Wenyi Gu | Director · Dec 10, 2024 – Dec 16, 2024 · Past |
Log in to ask 6ix AI your own questions about Anteris Technologies Global Corp.